Clinical trials: Stroke, open to volunteers
Acute Ischemic Stroke
A Study to Evaluate the Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in AIS Participant
This is a phase II, open-label, single-arm, exploratory study to evaluate the intracranial arterial recanalization of multiple doses of LT3001 drug product in participant with acute ischemic stroke (AIS)
- Trial name
- NCT07890298
- Testing
- LT3001 Drug Product
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Acute Ischemic Stroke
Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions
The goal of this clinical trials is to demonstrate the safety and effectiveness for the RapidPulseTM Aspiration System in patients experiencing acute ischemic stroke within 8 hours of symptom onset or last seen normal.
- Trial name
- TURBO (NCT06029491)
- Testing
- RapidPulseTM Aspiration System
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 170 people
- Sponsor
- RapidPulse, Inc
Atrial Fibrillation (AF)
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly.
- Trial name
- ROXI-ATLAS (NCT07175428)
- Testing
- REGN7508, REGN9933, Apixaban
- Where
- 89 sites in United States, Argentina and 2 more
- Volunteers
- 1,200 people
- Sponsor
- Regeneron Pharmaceuticals
Acute Ischemic Stroke (AIS)
Study to Collect Real-world Performance and Safety Data on Penumbra System® in Population With Acute Ischemic Stroke (AIS).
The primary objective of this study is to collect real-world performance and safety data on the Penumbra System in a patient population with acute ischemic stroke (AIS)
- Trial name
- i-RISE (NCT07107022)
- Testing
- Penumbra System ®
- Where
- 12 sites in Australia, Canada and 3 more
- Volunteers
- 200 people
- Sponsor
- Penumbra Inc.
Ischemic Stroke, Acute Stroke
Continuous Dual Aspiration Technique With Zoom System for Stroke
This study is designed to evaluate the effectiveness, safety and clinical performance of ADAPT 2.0, first-line aspiration neurothrombectomy with Zoom System with Continuous Dual Aspiration Technique (CDAT).
- Trial name
- ADAPT 2 0 (NCT07491952)
- Testing
- Zoom System
- Where
- 25 sites in United States
- Volunteers
- 750 people
- Sponsor
- Imperative Care, Inc.
Stroke, Stroke, Acute Ischemic
NeuroAiD Patient-Reported Outcomes in Patients With Mild to Moderate Ischemic Stroke
This is a randomized, controlled, open-label study of MLC901 (NeuroAiD™ II) in patients with mild to moderate ischemic stroke. Eligible participants will be randomized in a 1:1 ratio to receive MLC901 in combination with standard…
- Conditions
- Stroke, Stroke, Acute Ischemic, Stroke, Ischemic, Stroke, Cryptogenic
- Trial name
- NAiD-PRO (NCT07828210)
- Testing
- MLC901, Standard treatment for acute ischemic stroke
- Where
- Vietnam
- Volunteers
- 80 people
- Sponsor
- EVD Pharmacy and Medical Company Limited
Ischemic Stroke
Strategy for Improving Stroke Treatment Response
SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in…
- Trial name
- SISTER (NCT05948566)
- Testing
- TS23
- Where
- 52 sites in United States
- Volunteers
- 300 people
- Sponsor
- Translational Sciences, Inc.
Acute Ischemic Stroke
A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke
This phase II clinical study is designed to evaluate the efficacy and safety of LT3001 in the treatment of acute ischemic stroke
- Trial name
- NCT07754825
- Testing
- LT3001 Drug:high dose, LT3001 Drug: low dose
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Atrial Fibrillation (AF), Stroke
Elite AF IDE Trial (Elite AF)
The primary objective of this study is to establish the safety and effectiveness of the WATCHMAN Elite Left Atrial Appendage Closure (LAAC) Device for subjects with non-valvular atrial fibrillation who are eligible for…
- Trial name
- NCT07287436
- Testing
- WATCHMAN Elite LAAC Device
- Where
- 2 sites in United States
- Volunteers
- 400 people
- Sponsor
- Boston Scientific Corporation
Acute Ischemic Stroke, Acute Ischemic Stroke (AIS) Related to a Distal Occlusion
FORWARD: Functional Outcomes in Real-World Treatment And Revascularization of Non-dominant and Distal M2 Occlusions
The objective of this study is to collect safety and effectiveness data on the Penumbra System reperfusion catheters in participants with isolated primary non-dominant and distal M2 occlusions who undergo endovascular mechanical…
- Trial name
- NCT07749170
- Testing
- Endovascular Thrombectomy, Medical Management
- Where
- 5 sites in United States
- Volunteers
- 250 people
- Sponsor
- Penumbra Inc.
Secondary Stroke
A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants
This study will test an experimental Regeneron drug called cenvacibart (REGN7508) ("study drug") compared with a placebo (a look-alike treatment with no active medicine) on top of background antiplatelet medications.
- Trial name
- ROXI-DAISEN (NCT07876492)
- Testing
- Cenvacibart
- Volunteers
- 6,106 people
- Sponsor
- Regeneron Pharmaceuticals
Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD)
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
The KHENERFIN study aims to determine whether the study medicine, sonlicromanol, is able to reduce symptoms of fatigue and the impact of fatigue on daily life, and whether sonlicromanol is able to improve physical abilities of…
- Conditions
- Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS), Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
- Trial name
- KH176-301 (NCT06451757)
- Testing
- Sonlicromanol
- Where
- 10 sites in United States, Denmark and 5 more
- Volunteers
- 220 people
- Sponsor
- Khondrion BV
Stroke, Multiple Sclerosis
Evaluation of the NEUROSWING Orthosis on Walking Speed in a Population With Dorsal and/or Plantar Flexor Deficits, With a View to a Reimbursement Application
The aim of this randomized, cross-over, multi-center, intention-to-treat, open-label study study is to determine the benefits of the NEUROSWING device on gait speed in patients with dorsal and/or plantar flexor deficits, compared…
- Conditions
- Stroke, Multiple Sclerosis, Cerebral Palsy, Neuromuscular Deficits
- Trial name
- NS-BOOSST (NCT07108088)
- Testing
- NEUROSWING Orthosis (experimental) : carbon orthosis with an active ankle articulation, Carbon orthosis (control)
- Where
- 2 sites in France
- Volunteers
- 34 people
- Sponsor
- ÖSSUR France
Atrial Fibrillation (AF)
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.
- Trial name
- ROXI-INCLINE (NCT07430956)
- Testing
- REGN7508, REGN9933
- Where
- 44 sites in United States, Canada
- Volunteers
- 2,628 people
- Sponsor
- Regeneron Pharmaceuticals
Acute Ischemic Stroke
Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)
The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset.
- Trial name
- RAISE (NCT06226805)
- Testing
- BB-031
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 228 people
- Sponsor
- Basking Biosciences, Inc.
Hemorrhagic Stroke, Aneurysm, Intracranial
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
To determine safety and effectiveness of the p48 MW HPC and p64 MW HPC Flow Modulation Device in the treatment of wide-necked intracranial aneurysms.
- Conditions
- Hemorrhagic Stroke, Aneurysm, Intracranial, Saccular Aneurysm, Fusiform Aneurysm
- Trial name
- PIANO (NCT07143019)
- Testing
- Flow diversion
- Where
- 25 sites in United States
- Volunteers
- 214 people
- Sponsor
- phenox Inc.
Ischemic Stroke Hospitalized, Impairment, Cognitive
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
The goal of this clinical trial is to learn if Extract of Ginkgo Biloba Leaves Tablets help improve thinking and memory in people aged 55 years and older who had an ischemic stroke (a type of stroke caused by a blocked blood…
- Trial name
- GiCIIS (NCT07220538)
- Testing
- Extract of Ginkgo Biloba Leaves Tablets 240 mg (2 x 40 mg, t.i.d.), Standard of care (SoC) Group
- Where
- 40 sites in China
- Volunteers
- 400 people
- Sponsor
- Dr. Willmar Schwabe GmbH & Co. KG
Atrial Fibrillation (AF), Stroke Prevention in Patients With Atrial Fibrillation
OPTION-EMEA Clinical Trial
The OPTION-EMEA post-market study is intended to gather real world clinical data for patients undergoing AF ablation with the FARAPULSE™ Pulsed Field Ablation (PFA) System and subsequent left atrial appendage closure (LAAC) with…
- Conditions
- Atrial Fibrillation (AF), Stroke Prevention in Patients With Atrial Fibrillation, Left Atrial Appendage Closure, Pulsed Field Ablation
- Trial name
- OPTION-EMEA (NCT07349121)
- Testing
- Concomitant pulsed field ablation (PFA) and left atrial appendage closure (LAAC) during one interventional case, Concomitant Pulsed Field Ablation and Left Atrial Appendage Closure
- Where
- 5 sites in Belgium, Croatia and 3 more
- Volunteers
- 500 people
- Sponsor
- Boston Scientific Corporation
Acute Ischemic Stroke
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
This study is open to adults who had an acute stroke caused by a clot blocking a blood vessel in the brain (acute ischemic stroke).
- Trial name
- TENACITY (NCT07361302)
- Testing
- Tenecteplase, Standard of care treatment
- Where
- 254 sites in Argentina, Australia and 14 more
- Volunteers
- 1,325 people
- Sponsor
- Boehringer Ingelheim
Upper Extremity Problem
Vivistim Registry for Paired VNS Therapy (GRASP)
The purpose of the Vivistim Registry for Paired VNS Therapy (GRASP) is to gather real-world information on patients with arm and hand deficits post-stroke who are considering Vivistim System treatment.
- Trial name
- GRASP (NCT05301140)
- Testing
- Vivistim System
- Where
- 16 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- MicroTransponder Inc.